DELTA-1: A GLOBAL, MULTICENTER, PHASE 2 STUDY OF ITIL-168, AN UNRESTRICTED AUTOLOGOUS TUMORINFILTRATING LYMPHOCYTE (TIL) CELL THERAPY, IN ADULT PATIENTS WITH ADVANCED CUTANEOUS MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
SAFETY AND SURVIVAL RESULTS FROM A PHASE 1/2 TRIAL OF INTRATUMORAL AGENT INT230-6 (CISPLATIN VINBLASTINE) INDUCES IMMUNOLOGICAL CANCER CELL DEATH ALONE OR WITH PEMBROLIZUMAB IN PATIENTS WITH REFRACTORY, METASTATIC CANCERSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
REPEAT DOSING OF ONCOLYTIC ADENOVIRUS ONCOS-102 IS ASSOCIATED WITH ENHANCED AND PERSISTENT IMMUNE RESPONSES AND IMPROVED SYSTEMIC ACTIVITY IN ANTI-PD-1 RESISTANT/REFRACTORY (R/R) MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
SURVIVAL AND IMMUNE RESPONSE DATA FROM INTRATUMORAL INT230-6 ALONE (IT-01) AND WITH PEMBROLIZUMAB [KEYNOTE-A10] IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE AND METASTATIC SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-100OA
FIRST-IN-HUMAN PHASE 1/2 STUDY OF THE FIRST-IN-CLASS SUMO-ACTIVATING ENZYME INHIBITOR TAK-981 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS OR RELAPSED/REFRACTORY LYMPHOMA: PHASE 1 RESULTS首次在晚期或转移性实体瘤或复发/难治性淋巴瘤患者中TAK-981 SUMO激活酶抑制剂的人类1/2期研究: 1期结果JOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-104OA
INTRATUMORAL INT230-6 SHOWS A FAVORABLE SAFETY PROFILE AND EARLY SIGNS OF EFFICACY IN ADVANCED SOFT TISSUE SARCOMA WITH MONOTHERAPY AND IN COMBINATION WITH IPILIMUMAB [INTENSITY IT-01; BMS#CA184-592]JOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-100OA
PHASE I DOSE ESCALATION OF KD033, A PDL1-IL15 BISPECIFIC MOLECULE, IN METASTATIC AND ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-100OA
FINAL ANALYSIS: PHASE 1B STUDY INVESTIGATING INTRATUMORAL INJECTION OF TOLL-LIKE RECEPTOR 9 AGONIST VIDUTOLIMOD ± PEMBROLIZUMAB IN PATIENTS WITH PD-1 BLOCKADE-REFRACTORY MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-106OA
PHASE I CLINICAL TRIAL EVALUATING THE SAFETY OF ADP-A2M10 SPEAR T-CELLS IN PATIENTS WITH MAGE-A10+ ADVANCED NON-SMALL CELL LUNG CANCERJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-12-101PREAI
A PHASE 1/1B DOSE-ESCALATION STUDY OF INTRAVENOUSLY ADMINISTERED SB 11285 ALONE AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-090PREAI
NOVEL INTRATUMORAL AGENT, INT230-6 INDUCES CANCER CELL DEATH, INCREASES TUMOR INFILTRATES AND RESULTS IN DURABLE BENEFIT ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN REFRACTORY PATIENTSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-090OAAI